Propyphenazone, also known as isopropylantipyrine in Japan, is a pyrazolone derivative with analgesic, antipyretic, and anti-inflammatory properties. It was originally patented in 1931 and introduced in 1951 for the treatment of rheumatic disorders. It is commonly used in combination with paracetamol and caffeine to treat primary headache disorders.
Despite its therapeutic benefits, propyphenazone has been associated with severe adverse effects, including blood dyscrasias and rare cases of myocardial infarction (Kounis syndrome). It is banned in some countries such as Sri Lanka, Malaysia, and Thailand due to safety concerns.
Chemical Structure
Propyphenazone has the molecular formula C14H18N2O and a molar mass of 230.31 g/mol. Its IUPAC name is 1,5-dimethyl-2-phenyl-4-(propan-2-yl)-2,3-dihydro-1H-pyrazol-3-one. The compound features a pyrazolone ring substituted with phenyl and isopropyl groups. Its structure is characterized by two methyl groups, a phenyl ring, and an isopropyl substituent attached to the pyrazolone core. The SMILES notation is CC(C)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1.
Propyphenazone-Based Medicines
Propyphenazone is often formulated in combination with other drugs to enhance its analgesic and antipyretic effects. Some notable combination medicines include:
- Propyphenazone + Paracetamol + Caffeine (commonly used for headache relief)
- Propyphenazone + Psycholeptics (for pain with anxiety)
- Propyphenazone alone or in various combination formulations depending on regional availability
Due to regulatory restrictions, specific brand names vary by country, and some formulations may be restricted or banned in certain regions.
Mechanism of Action
Propyphenazone exerts its effects primarily through inhibition of cyclooxygenase (COX) enzymes, leading to reduced synthesis of prostaglandins which mediate pain, inflammation, and fever. This non-selective inhibition of COX enzymes underlies its analgesic, anti-inflammatory, and antipyretic properties.
It is structurally related to aminophenazone but does not form carcinogenic nitrosamines, making it a safer alternative in that respect.
Pharmacokinetics
Detailed pharmacokinetic data for propyphenazone are limited in the public domain. Generally, it is administered orally and absorbed through the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily via the kidneys. Its plasma half-life and metabolic pathways resemble those of other pyrazolone derivatives, but specific parameters require further study.
Therapeutic Uses
| Indication | Description |
|---|---|
| Primary headache disorders | Relief of migraine and tension headaches, often in combination with paracetamol and caffeine |
| Rheumatic disorders | Treatment of inflammation and pain associated with rheumatic diseases |
| Fever | Reduction of fever through antipyretic action |
| General analgesia | Management of mild to moderate pain |
Propyphenazone is mainly used for symptomatic relief of pain and fever, frequently in combination with other analgesics.
Side Effects
Propyphenazone has been associated with several adverse effects, some of which can be severe:
- Blood dyscrasias including agranulocytosis and aplastic anemia
- Hypersensitivity reactions, including rare cases of Kounis syndrome (allergic acute myocardial infarction)
- Gastrointestinal disturbances
- Allergic skin reactions
- Potential nephrotoxicity with prolonged use
Due to these risks, caution is advised, and monitoring for hematological abnormalities is recommended during prolonged therapy.
Drug Interactions
Propyphenazone may interact with several medications:
- It may decrease the excretion rate of benznidazole, potentially increasing serum levels of the latter.
- It can increase the risk or severity of hypertension when combined with certain drugs.
- Concomitant use with other nephrotoxic or hypertensive agents should be monitored carefully.
These interactions necessitate careful consideration when prescribing propyphenazone alongside other medications.
Safety Considerations
Because of its potential to cause severe blood disorders and hypersensitivity reactions, propyphenazone should be used with caution. It is contraindicated in patients with a history of blood dyscrasias or hypersensitivity to pyrazolones. Due to its adverse effect profile, some countries have restricted or banned its use. Patients should be advised to report any unusual symptoms such as fever, sore throat, or rash promptly.
Regulatory Status
Propyphenazone is approved for use in several countries but is banned in others, including Sri Lanka, Malaysia, and Thailand, due to safety concerns. Its availability as an over-the-counter medication varies by region, with some countries limiting its indications or requiring prescription-only status. Regulatory agencies continue to monitor its safety profile1.
In summary, propyphenazone is a pyrazolone derivative with analgesic, antipyretic, and anti-inflammatory properties used primarily for headache and rheumatic pain relief. While effective, its use is limited by serious adverse effects such as blood dyscrasias and hypersensitivity reactions, leading to restrictions or bans in some countries. It remains a valuable therapeutic agent when used judiciously and with appropriate monitoring.
